Champions Oncology Q3 revenue $12.8M (-3.2% YoY), operating loss $2.5M, adj EBITDA -$1.6M

CHAMPIONS ONCOLOGY, INC.

2023-Q3 EPS reported -$0.20 revenue$40,799,000

Revenue declined 3.2% to $12.8M from $13.2M a year ago, driven by macro-related customer cancellations.
Operating loss of $2.5M vs income of $0.83M in prior year; adjusted EBITDA loss of $1.6M vs positive $1.5M.
Record quarterly bookings; cash on hand $11.6M with no debt; net cash from ops $1.6M in Q3.
R&D spend increased $1.0M (46.8%) to $3.2M, mainly for therapeutic target discovery platform.
CEO expects improved results in fiscal 2024; YTD revenue up 12.6% to $40.8M but operating loss of $2.7M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CHAMPIONS ONCOLOGY, INC. reported third quarter of fiscal 2023, ended January 31, 2023 results: revenue $12.8 million.

Period: third quarter of fiscal 2023, ended January 31, 2023
Revenue: $12.8 million
Result: reported results

Exact text from the filing

Champions Oncology Reports Quarterly Revenue of $12.8 Million

View on SEC.gov

23 earnings releases filed in the last 30 days. Browse all earnings releases →

CHAMPIONS ONCOLOGY, INC. filing history →

Source: SEC EDGAR

accession 0001628280-23-008080

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.